Cresco Labs (CRLBF) and Its Competitors Financial Review

Cresco Labs (OTCMKTS:CRLBFGet Rating) is one of 51 publicly-traded companies in the “Medicinals & botanicals” industry, but how does it compare to its rivals? We will compare Cresco Labs to related companies based on the strength of its earnings, risk, valuation, institutional ownership, analyst recommendations, profitability and dividends.

Institutional & Insider Ownership

0.2% of Cresco Labs shares are owned by institutional investors. Comparatively, 16.1% of shares of all “Medicinals & botanicals” companies are owned by institutional investors. 25.2% of shares of all “Medicinals & botanicals” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Cresco Labs and its rivals revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Cresco Labs $821.68 million -$319.60 million -2.54
Cresco Labs Competitors $256.05 million -$63.83 million -7.40

Cresco Labs has higher revenue, but lower earnings than its rivals. Cresco Labs is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Cresco Labs and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cresco Labs -37.03% -1.46% -0.69%
Cresco Labs Competitors 1,001.95% -148.62% 145.00%

Analyst Ratings

This is a summary of current ratings and price targets for Cresco Labs and its rivals, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cresco Labs 0 0 7 0 3.00
Cresco Labs Competitors 150 495 605 26 2.40

Cresco Labs presently has a consensus target price of $15.58, indicating a potential upside of 416.00%. As a group, “Medicinals & botanicals” companies have a potential upside of 124.17%. Given Cresco Labs’ stronger consensus rating and higher probable upside, research analysts clearly believe Cresco Labs is more favorable than its rivals.

About Cresco Labs (Get Rating)

Cresco Labs Inc., together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand, as well as cannabis products under the Reserve brand. The company also offers cannabis flowers under the FloraCal brand; and chocolate and toffee confections, fruit-forward gummies, hard sweets, and taffy under the Mindy's Edibles brand, as well as licenses the Kiva brand, which produces cannabis infused edibles, including chocolate confections, gummies, mints, and tarts. In addition, the company offers cannabis-infused edibles under the Sunnyside brand. As of January 27, 2022, it owned and operated 48 dispensaries. The company was incorporated in 1990 and is headquartered in Chicago, Illinois.

Want More Great Investing Ideas?

Receive News & Ratings for Cresco Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cresco Labs and related companies with MarketBeat.com's FREE daily email newsletter.